Genenta Science S.p.A. has announced ongoing developments in its clinical studies targeting glioblastoma multiforme and genitourinary tumors. In the glioblastoma multiforme (TEM-GBM) study, 38 patients have been enrolled, with 25 receiving the investigational treatment, Temferon. Notably, two patients in the long-term follow-up study have survived three years post-surgery, with observations suggesting potential Temferon-mediated control of disease progression. These findings may require further investigation in larger trials. Simultaneously, Genenta has initiated the TEM-GU Phase 1 study, which aims to enroll 12 patients with genitourinary tumors. This study seeks to evaluate the safety and tolerability of Temferon in patients with Metastatic Renal Cell Carcinoma, using a fixed dose of genetically modified cells. The trial will also explore Temferon's potential synergy with immune checkpoint inhibitors or tyrosine kinase inhibitors. Results of this study will be presented in the future, once sufficient data is collected to allow for meaningful analysis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.